Literature DB >> 12015736

Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?

Valerie Speirs1.   

Abstract

Two oestrogen receptors (ERs), ER alpha and ER beta, have been identified. ER alpha is by far the better characterized and is an established predictive marker in breast cancer which influences decisions on whether or not to give adjuvant anti-oestrogens, such as tamoxifen. In contrast, the function of ER beta in breast pathobiology is unclear, partly because most studies have focused on its mRNA rather than the protein. In this review, the significance of ER beta in the human breast is reviewed with respect to recent literature and its possible implications are discussed. Copyright 2002 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12015736     DOI: 10.1002/path.1072

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  21 in total

1.  Estrogen receptors ER alpha and ER beta in proliferation in the rodent mammary gland.

Authors:  Guojun Cheng; Zhang Weihua; Margaret Warner; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-04       Impact factor: 11.205

2.  Estrogen receptor beta (ERbeta) protein expression correlates with BAG-1 and prognosis in brain glial tumours.

Authors:  Anna Batistatou; Panayiotis A Kyzas; Ann Goussia; Evdokia Arkoumani; Spyridon Voulgaris; Konstantinos Polyzoidis; Niki J Agnantis; Dimitrios Stefanou
Journal:  J Neurooncol       Date:  2005-11-15       Impact factor: 4.130

3.  Potential clinical significance of ERβ ON promoter methylation in sporadic breast cancer.

Authors:  Ana Božović; Milan Markićević; Bogomir Dimitrijević; Snežana Jovanović Ćupić; Milena Krajnović; Silvana Lukić; Vesna Mandušić
Journal:  Med Oncol       Date:  2013-06-22       Impact factor: 3.064

4.  Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor beta on mRNA stability and translatability.

Authors:  Milica Putnik; Chunyan Zhao; Jan-Ake Gustafsson; Karin Dahlman-Wright
Journal:  BMC Genet       Date:  2009-09-15       Impact factor: 2.797

5.  The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer.

Authors:  L Nakopoulou; A C Lazaris; E G Panayotopoulou; I Giannopoulou; N Givalos; S Markaki; A Keramopoulos
Journal:  J Clin Pathol       Date:  2004-05       Impact factor: 3.411

6.  Estrogen receptor beta (ERbeta) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm.

Authors:  Anna Batistatou; Dimitrios Stefanou; Anna Goussia; Evdokia Arkoumani; Athanasios G Papavassiliou; Niki J Agnantis
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

7.  Aromatase and estrogen receptor alpha mRNA expression as prognostic biomarkers in patients with astrocytomas.

Authors:  J M Dueñas Jiménez; A Candanedo Arellano; A Santerre; S Orozco Suárez; H Sandoval Sánchez; I Feria Romero; R López-Elizalde; M Alonso Venegas; B Netel; B de la Torre Valdovinos; S H Dueñas Jiménez
Journal:  J Neurooncol       Date:  2014-07-09       Impact factor: 4.130

8.  Gene expression markers in circulating tumor cells may predict bone metastasis and response to hormonal treatment in breast cancer.

Authors:  Haiying Wang; Julian Molina; John Jiang; Matthew Ferber; Sandhya Pruthi; Timothy Jatkoe; Carlo Derecho; Yashoda Rajpurohit; Jian Zheng; Yixin Wang
Journal:  Mol Clin Oncol       Date:  2013-08-02

9.  Expression of estrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer.

Authors:  Vesna Mandusić; Dragica Nikolić-Vukosavljević; Nikola Tanić; Ksenija Kanjer; Zora Neskovic-Konstantinović; Dusica Celeketić; Bogomir Dimitrijević
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-25       Impact factor: 4.322

10.  Association of oestrogen receptor beta 2 (ER beta 2/ER beta cx) with outcome of adjuvant endocrine treatment for primary breast cancer--a retrospective study.

Authors:  Raman Vinayagam; D Ross Sibson; Christopher Holcombe; Vijay Aachi; Michael Pa Davies
Journal:  BMC Cancer       Date:  2007-07-18       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.